Candel Therapeutics Partners with Bristol Myers Squibb for Cancer Trial

TL;DR

Candel teams up with BMS for new cancer combo trial starting H2 2024.

AI Summary

Candel Therapeutics, Inc. announced on April 11, 2024, that it has entered into a clinical trial collaboration with Bristol Myers Squibb. This collaboration will evaluate the combination of Candel's oncolytic virus, CAN-2404, with Bristol Myers Squibb's PD-1 inhibitor, Opdualag (nivolumab and relatlimab-rmbw), in patients with advanced solid tumors. The trial is expected to begin in the second half of 2024.

Why It Matters

This collaboration could significantly advance Candel's lead drug candidate by combining it with a well-established immunotherapy, potentially leading to improved treatment options for cancer patients.

Risk Assessment

Risk Level: medium — The success of the clinical trial is uncertain, and the combination therapy may not prove effective or safe, impacting Candel's future prospects.

Key Players & Entities

• Candel Therapeutics, Inc. (company) — Registrant
• Bristol Myers Squibb (company) — Collaboration Partner
• CAN-2404 (drug) — Candel's oncolytic virus
• Opdualag (drug) — Bristol Myers Squibb's PD-1 inhibitor
• nivolumab and relatlimab-rmbw (drug) — Components of Opdualag
• April 11, 2024 (date) — Date of Report
• second half of 2024 (date) — Expected trial start

FAQ

Key Financial Figures

• $0.01 — nge on which registered Common Stock, $0.01 par value per share CADL The Nasdaq

Filing Documents

• cadl-20240411.htm (8-K) — 45KB
• cadl-ex99_1.htm (EX-99.1) — 26KB
• img160460863_0.jpg (GRAPHIC) — 21KB
• 0000950170-24-043532.txt ( ) — 224KB
• cadl-20240411.xsd (EX-101.SCH) — 27KB
• cadl-20240411_htm.xml (XML) — 5KB

01 Regulation FD Disclosure

Item 7.01 Regulation FD Disclosure. On April 11, 2024, Candel Therapeutics, Inc. (the "Company") issued a press release announcing that the United States Food and Drug Administration (the "FDA") has granted Orphan Drug Designation for CAN-2409 for the treatment of pancreatic cancer. A copy of the full press release announcing such Orphan Drug Designation is attached as Exhibit 99.1 to this Current Report on Form 8-K and incorporated by reference herein. The information in this Item 7.01 and Exhibit 99.1 of this Current Report on Form 8-K is furnished and shall not be deemed to be "filed" for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that section. The information in this Item 7.01 and Exhibit 99.1 of this Current Report on Form 8-K shall not be incorporated by reference into any filing under the Securities Act of 1933, as amended, or the Exchange Act, whether made before or after the date of this Current Report on Form 8-K, regardless of any general incorporation language in any such filing.

01 Other Events

Item 8.01 Other Events. On April 11, 2024, the Company announced that the FDA has granted Orphan Drug Designation for CAN-2409 for the treatment of pancreatic cancer.

01 Financial Statements and Exhibits

Item 9.01 Financial Statements and Exhibits. (d) Exhibits Exhibit Number Description 99.1 Press Release dated April 11, 2024 104 Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Candel Therapeutics, Inc. Date: April 11, 2024 By: /s/ Paul Peter Tak Paul Peter Tak, M.D., Ph.D., FMedSci President and Chief Executive Officer

View Full Filing

View this 8-K filing on SEC EDGAR